Sequential transplants using mobilized peripheral blood progenitor cells

R. Ghalie, Carol M Richman, J. G. Bender, B. C. McLeod, W. Lee, A. Czyzewski, S. Manson, M. A. Cobleigh, S. Reed, R. Pierre, S. George, H. Kaizer

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Modest success has been achieved with the use of high-dose cytotoxic therapy and bone marrow transplantation in solid tumors. Patient outcome can potentially be improved with further intensification of the therapy. The rapid hematologic recovery achieved with mobilized peripheral blood progenitor cells (PBPC) may reduce the toxicity of transplantation enabling the use of sequential courses of myeloablative therapy. We report on 42 patients with solid tumors enrolled in a tandem transplant protocol involving the use of PBPC mobilized with cyclophosphamide (4 g/m2), etoposide (1 g/m2), and granulocyte-colony-stimulating factor (G-CSF: 10 μg/kg/day). This regimen significantly increased the number of circulating progenitor cells; only 1-2 aphereses were sufficient to collect 2.5 x 108/kg mononuclear cells, our goal for each transplant course. The median number of circulating colony-forming units (CFU) and CD34+ cells obtained for each transplant course were 70.3 x 104/kg and 11.7 x 106/kg, respectively. There was a significant correlation between the numbers of CD34+ cells and CFU measured in the apheresis product (r = 0.49, P = .003). The first transplant regimen given to 38 patients consisted of thiotepa, carboplatin, and cyclophosphamide. The second transplant regimen given to 29 patients consisted of busulfan and etoposide. Hematologic recovery was comparable after each of the two transplant courses. The median time to neutrophil recovery over 0.5 x 109/L and to platelet transfusion independence was 9 and 8 days, respectively. There was no difference in engraftment rates after transplant with PBPC only (n = 28 courses) compared to transplant with PBPC plus bone marrow (n = 39 courses). There was a significant correlation between hematologic recovery after transplant and the number of CD34+ cells present in the PBPC. In conclusion, 1) PBPC are significantly mobilized with this combination chemotherapy and G-CSF, 2) mobilized PBPC result in rapid engraftment after myeloablative therapy, 3) hematologic recovery rates are comparable after sequential PBPC transplants, 4) PBPC alone are sufficient for long-term engraftment, and 5) rapid engraftment after PBPC transplant enables the use of a second course of myeloablative therapy within a short interval of time.

Original languageEnglish (US)
Pages (from-to)176-182
Number of pages7
JournalJournal of Clinical Apheresis
Volume9
Issue number3
DOIs
StatePublished - 1994

Fingerprint

Blood Cells
Stem Cells
Transplants
Granulocyte Colony-Stimulating Factor
Blood Component Removal
Etoposide
Cyclophosphamide
Cell Count
Thiotepa
Therapeutics
Busulfan
Platelet Transfusion
Carboplatin
Granulocyte-Macrophage Colony-Stimulating Factor
Combination Drug Therapy
Bone Marrow Transplantation
Neoplasms
Neutrophils
Transplantation
Bone Marrow

ASJC Scopus subject areas

  • Hematology

Cite this

Ghalie, R., Richman, C. M., Bender, J. G., McLeod, B. C., Lee, W., Czyzewski, A., ... Kaizer, H. (1994). Sequential transplants using mobilized peripheral blood progenitor cells. Journal of Clinical Apheresis, 9(3), 176-182. https://doi.org/10.1002/jca.2920090307

Sequential transplants using mobilized peripheral blood progenitor cells. / Ghalie, R.; Richman, Carol M; Bender, J. G.; McLeod, B. C.; Lee, W.; Czyzewski, A.; Manson, S.; Cobleigh, M. A.; Reed, S.; Pierre, R.; George, S.; Kaizer, H.

In: Journal of Clinical Apheresis, Vol. 9, No. 3, 1994, p. 176-182.

Research output: Contribution to journalArticle

Ghalie, R, Richman, CM, Bender, JG, McLeod, BC, Lee, W, Czyzewski, A, Manson, S, Cobleigh, MA, Reed, S, Pierre, R, George, S & Kaizer, H 1994, 'Sequential transplants using mobilized peripheral blood progenitor cells', Journal of Clinical Apheresis, vol. 9, no. 3, pp. 176-182. https://doi.org/10.1002/jca.2920090307
Ghalie, R. ; Richman, Carol M ; Bender, J. G. ; McLeod, B. C. ; Lee, W. ; Czyzewski, A. ; Manson, S. ; Cobleigh, M. A. ; Reed, S. ; Pierre, R. ; George, S. ; Kaizer, H. / Sequential transplants using mobilized peripheral blood progenitor cells. In: Journal of Clinical Apheresis. 1994 ; Vol. 9, No. 3. pp. 176-182.
@article{5bc82a5ccdfc47a3a8df1450d8c6c1dc,
title = "Sequential transplants using mobilized peripheral blood progenitor cells",
abstract = "Modest success has been achieved with the use of high-dose cytotoxic therapy and bone marrow transplantation in solid tumors. Patient outcome can potentially be improved with further intensification of the therapy. The rapid hematologic recovery achieved with mobilized peripheral blood progenitor cells (PBPC) may reduce the toxicity of transplantation enabling the use of sequential courses of myeloablative therapy. We report on 42 patients with solid tumors enrolled in a tandem transplant protocol involving the use of PBPC mobilized with cyclophosphamide (4 g/m2), etoposide (1 g/m2), and granulocyte-colony-stimulating factor (G-CSF: 10 μg/kg/day). This regimen significantly increased the number of circulating progenitor cells; only 1-2 aphereses were sufficient to collect 2.5 x 108/kg mononuclear cells, our goal for each transplant course. The median number of circulating colony-forming units (CFU) and CD34+ cells obtained for each transplant course were 70.3 x 104/kg and 11.7 x 106/kg, respectively. There was a significant correlation between the numbers of CD34+ cells and CFU measured in the apheresis product (r = 0.49, P = .003). The first transplant regimen given to 38 patients consisted of thiotepa, carboplatin, and cyclophosphamide. The second transplant regimen given to 29 patients consisted of busulfan and etoposide. Hematologic recovery was comparable after each of the two transplant courses. The median time to neutrophil recovery over 0.5 x 109/L and to platelet transfusion independence was 9 and 8 days, respectively. There was no difference in engraftment rates after transplant with PBPC only (n = 28 courses) compared to transplant with PBPC plus bone marrow (n = 39 courses). There was a significant correlation between hematologic recovery after transplant and the number of CD34+ cells present in the PBPC. In conclusion, 1) PBPC are significantly mobilized with this combination chemotherapy and G-CSF, 2) mobilized PBPC result in rapid engraftment after myeloablative therapy, 3) hematologic recovery rates are comparable after sequential PBPC transplants, 4) PBPC alone are sufficient for long-term engraftment, and 5) rapid engraftment after PBPC transplant enables the use of a second course of myeloablative therapy within a short interval of time.",
author = "R. Ghalie and Richman, {Carol M} and Bender, {J. G.} and McLeod, {B. C.} and W. Lee and A. Czyzewski and S. Manson and Cobleigh, {M. A.} and S. Reed and R. Pierre and S. George and H. Kaizer",
year = "1994",
doi = "10.1002/jca.2920090307",
language = "English (US)",
volume = "9",
pages = "176--182",
journal = "Journal of Clinical Apheresis",
issn = "0733-2459",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Sequential transplants using mobilized peripheral blood progenitor cells

AU - Ghalie, R.

AU - Richman, Carol M

AU - Bender, J. G.

AU - McLeod, B. C.

AU - Lee, W.

AU - Czyzewski, A.

AU - Manson, S.

AU - Cobleigh, M. A.

AU - Reed, S.

AU - Pierre, R.

AU - George, S.

AU - Kaizer, H.

PY - 1994

Y1 - 1994

N2 - Modest success has been achieved with the use of high-dose cytotoxic therapy and bone marrow transplantation in solid tumors. Patient outcome can potentially be improved with further intensification of the therapy. The rapid hematologic recovery achieved with mobilized peripheral blood progenitor cells (PBPC) may reduce the toxicity of transplantation enabling the use of sequential courses of myeloablative therapy. We report on 42 patients with solid tumors enrolled in a tandem transplant protocol involving the use of PBPC mobilized with cyclophosphamide (4 g/m2), etoposide (1 g/m2), and granulocyte-colony-stimulating factor (G-CSF: 10 μg/kg/day). This regimen significantly increased the number of circulating progenitor cells; only 1-2 aphereses were sufficient to collect 2.5 x 108/kg mononuclear cells, our goal for each transplant course. The median number of circulating colony-forming units (CFU) and CD34+ cells obtained for each transplant course were 70.3 x 104/kg and 11.7 x 106/kg, respectively. There was a significant correlation between the numbers of CD34+ cells and CFU measured in the apheresis product (r = 0.49, P = .003). The first transplant regimen given to 38 patients consisted of thiotepa, carboplatin, and cyclophosphamide. The second transplant regimen given to 29 patients consisted of busulfan and etoposide. Hematologic recovery was comparable after each of the two transplant courses. The median time to neutrophil recovery over 0.5 x 109/L and to platelet transfusion independence was 9 and 8 days, respectively. There was no difference in engraftment rates after transplant with PBPC only (n = 28 courses) compared to transplant with PBPC plus bone marrow (n = 39 courses). There was a significant correlation between hematologic recovery after transplant and the number of CD34+ cells present in the PBPC. In conclusion, 1) PBPC are significantly mobilized with this combination chemotherapy and G-CSF, 2) mobilized PBPC result in rapid engraftment after myeloablative therapy, 3) hematologic recovery rates are comparable after sequential PBPC transplants, 4) PBPC alone are sufficient for long-term engraftment, and 5) rapid engraftment after PBPC transplant enables the use of a second course of myeloablative therapy within a short interval of time.

AB - Modest success has been achieved with the use of high-dose cytotoxic therapy and bone marrow transplantation in solid tumors. Patient outcome can potentially be improved with further intensification of the therapy. The rapid hematologic recovery achieved with mobilized peripheral blood progenitor cells (PBPC) may reduce the toxicity of transplantation enabling the use of sequential courses of myeloablative therapy. We report on 42 patients with solid tumors enrolled in a tandem transplant protocol involving the use of PBPC mobilized with cyclophosphamide (4 g/m2), etoposide (1 g/m2), and granulocyte-colony-stimulating factor (G-CSF: 10 μg/kg/day). This regimen significantly increased the number of circulating progenitor cells; only 1-2 aphereses were sufficient to collect 2.5 x 108/kg mononuclear cells, our goal for each transplant course. The median number of circulating colony-forming units (CFU) and CD34+ cells obtained for each transplant course were 70.3 x 104/kg and 11.7 x 106/kg, respectively. There was a significant correlation between the numbers of CD34+ cells and CFU measured in the apheresis product (r = 0.49, P = .003). The first transplant regimen given to 38 patients consisted of thiotepa, carboplatin, and cyclophosphamide. The second transplant regimen given to 29 patients consisted of busulfan and etoposide. Hematologic recovery was comparable after each of the two transplant courses. The median time to neutrophil recovery over 0.5 x 109/L and to platelet transfusion independence was 9 and 8 days, respectively. There was no difference in engraftment rates after transplant with PBPC only (n = 28 courses) compared to transplant with PBPC plus bone marrow (n = 39 courses). There was a significant correlation between hematologic recovery after transplant and the number of CD34+ cells present in the PBPC. In conclusion, 1) PBPC are significantly mobilized with this combination chemotherapy and G-CSF, 2) mobilized PBPC result in rapid engraftment after myeloablative therapy, 3) hematologic recovery rates are comparable after sequential PBPC transplants, 4) PBPC alone are sufficient for long-term engraftment, and 5) rapid engraftment after PBPC transplant enables the use of a second course of myeloablative therapy within a short interval of time.

UR - http://www.scopus.com/inward/record.url?scp=0028557103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028557103&partnerID=8YFLogxK

U2 - 10.1002/jca.2920090307

DO - 10.1002/jca.2920090307

M3 - Article

C2 - 7535760

AN - SCOPUS:0028557103

VL - 9

SP - 176

EP - 182

JO - Journal of Clinical Apheresis

JF - Journal of Clinical Apheresis

SN - 0733-2459

IS - 3

ER -